Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells

被引:160
作者
Valmori, Danila [1 ]
Tosello, Valeria [1 ]
Souleimanian, Naira E. [1 ]
Godefroy, Emmanuelle [1 ]
Scotto, Luigi [1 ]
Wang, Yu [1 ]
Ayyoub, Maha [1 ]
机构
[1] Columbia Univ Coll Phys & Surg, Dept Med, Div Med Oncol, Ludwig Inst Clin Trials Ctr, New York, NY 10032 USA
关键词
D O I
10.4049/jimmunol.177.2.944
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Rapamycin is an immunosuppressive drug currently used in different clinical settings. Although the capacity of rapamycin to inhibit the mammalian target of rapamycin serine/threonine protein kinase and therefore T cell cycle progression is well known, its effects are complex and not completely understood. It has been reported recently that TCR-mediated stimulation of murine CD4(+) T cells in the presence of rapamycin results in increased proportions of CD4(+) T cells with suppressive functions, suggesting that the drug may also exert its immunosuppressive activity by promoting the selective expansion of naturally occurring CD4(+) regulatory T cells (Treg). In this study, we show that stimulation of human circulating CD4(+) T cells in the presence of rapamycin results indeed in highly increased suppressor activity. By assessing the effect of rap mycin on the growth of nonregulatory and Treg populations of defined differentiation stages purified ex vivo from circulating CD4(+) T cells, we could demonstrate that this phenomenon is not due to a selective expansion of naturally occurring Tregs, but to the capacity of rapamycin to induce, upon TCR-mediated stimulation, suppressor functions in conventional CD4(+) T cells. This condition, however, is temporary and reversible as it is dependent upon the continuous presence of rapamycin.
引用
收藏
页码:944 / 949
页数:6
相关论文
共 25 条
[1]   Immunopharmacology of rapamycin [J].
Abraham, RT ;
Wiederrecht, GJ .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :483-510
[2]   Regulatory T cells under scrutiny [J].
Bach, JF .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (03) :189-198
[3]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[4]   Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells [J].
Battaglia, M ;
Stabilini, A ;
Roncarolo, MG .
BLOOD, 2005, 105 (12) :4743-4748
[5]   CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity [J].
Belkaid, Y ;
Piccirillo, CA ;
Mendez, S ;
Shevach, EM ;
Sacks, DL .
NATURE, 2002, 420 (6915) :502-507
[6]   The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade [J].
Blaha, P ;
Bigenzahn, S ;
Koporc, Z ;
Schmid, M ;
Langer, F ;
Selzer, E ;
Bergmeister, H ;
Wrba, F ;
Kurtz, J ;
Kiss, C ;
Roth, E ;
Muehlbacher, F ;
Sykes, M ;
Wekerle, T .
BLOOD, 2003, 101 (07) :2886-2893
[7]   Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells [J].
Boulay, A ;
Zumstein-Mecker, S ;
Stephan, C ;
Beuvink, I ;
Zilbermann, F ;
Haller, R ;
Tobler, S ;
Heusser, C ;
O'Reilly, T ;
Stolz, B ;
Marti, A ;
Thomas, G ;
Lane, HA .
CANCER RESEARCH, 2004, 64 (01) :252-261
[8]  
Chai JG, 1999, EUR J IMMUNOL, V29, P686, DOI 10.1002/(SICI)1521-4141(199902)29:02<686::AID-IMMU686>3.0.CO
[9]  
2-N
[10]   CD4+CD25+ immunoregulatory T cells:: New therapeutics for graft-versus-host disease [J].
Cohen, JL ;
Trenado, A ;
Vasey, D ;
Klatzmann, D ;
Salomon, BL .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :401-406